Targeting RhoA/ROCK pathway in pulmonary arterial hypertension

Bibliography

• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36
   PubMed Web of Science ®Google Scholar
• Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J 2011;37:665-77
   PubMed Web of Science ®Google Scholar
• Nakagawa O, Fujisawa K, Ishizaki T, ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 1996;392:189-93
   PubMed Web of Science ®Google Scholar
• Amano M, Nakayama M, Kaibuchi K. Rho-kinase/rock: A key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken) 2010;67:545-54
   PubMed Web of Science ®Google Scholar
• Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006;98:322-34
   PubMed Web of Science ®Google Scholar
• Leung T, Chen XQ, Manser E, Lim L. The p160 RhoA-binding kinase ROKalpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 1996;16:5313-27
   PubMed Web of Science ®Google Scholar
• Matsui T, Amano M, Yamamoto T, Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. Embo J 1996;15:2208-16
   PubMed Web of Science ®Google Scholar
• Narumiya S. The small GTPase Rho: cellular functions and signal transduction. J Biochem 1996;120:215-28
   PubMed Web of Science ®Google Scholar
• Amano M, Mukai H, Ono Y, Identification of a putative target for Rho as the serine-threonine kinase protein kinase N. Science 1996;271:648-50
   PubMed Web of Science ®Google Scholar
• Hiroki J, Shimokawa H, Higashi M, Inflammatory stimuli upregulate Rho-kinase in human coronary vascular smooth muscle cells. J Mol Cell Cardiol 2004;37:537-46
   PubMed Web of Science ®Google Scholar
• Maekawa M, Ishizaki T, Boku S, Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 1999;285:895-8
   PubMed Web of Science ®Google Scholar
• Amano M, Chihara K, Kimura K, Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 1997;275:1308-11
   PubMed Web of Science ®Google Scholar
• Somlyo AV. Cyclic GMP regulation of myosin phosphatase: a new piece for the puzzle? Circ Res 2007;101:645-7
   PubMed Web of Science ®Google Scholar
• Thumkeo D, Keel J, Ishizaki T, Targeted disruption of the mouse Rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol 2003;23:5043-55
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Thumkeo D, Keel J, ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol 2005;168:941-53
   PubMed Web of Science ®Google Scholar
• Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 2007;28:296-302
   PubMed Web of Science ®Google Scholar
• Guilluy C, Eddahibi S, Agard C, RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am J Respir Crit Care Med 2009;179:1151-8
   PubMed Web of Science ®Google Scholar
• Do EZ, Fukumoto Y, Takaki A, Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J 2009;73:1731-9
   PubMedGoogle Scholar
• Guilluy C, Rolli-Derkinderen M, Tharaux PL, Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells. J Biol Chem 2007;282:2918-28
   PubMedGoogle Scholar
• Liu AJ, Ling F, Wang D, Fasudil inhibits platelet-derived growth factor-induced human pulmonary artery smooth muscle cell proliferation by up-regulation of p27kip1 via the ERK signal pathway. Chin Med J (Engl) 2011;124:3098-104
   PubMed Web of Science ®Google Scholar
• Wang Z, Jin N, Ganguli S, Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction. Am J Respir Cell Mol Biol 2001;25:628-35
   PubMed Web of Science ®Google Scholar
• Nagaoka T, Gebb SA, Karoor V, Involvement of rhoa/rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. J Appl Physiol 2006;100:996-1002
   PubMed Web of Science ®Google Scholar
• Taraseviciene-Stewart L, Kasahara Y, Alger L, Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. Faseb J 2001;15:427-38
   PubMed Web of Science ®Google Scholar
• Oka M, Homma N, Taraseviciene-Stewart L, Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007;100:923-9
   PubMed Web of Science ®Google Scholar
• Godin CM, Ferguson SS. The angiotensin II type 1 receptor induces membrane blebbing by coupling to Rho A, Rho kinase, and myosin light chain kinase. Mol Pharmacol 77:903-11
   PubMedGoogle Scholar
• Lima VV, Giachini FR, Carneiro FS, O-GlcNAcylation contributes to the vascular effects of ET-1 via activation of the RhoA/Rho-kinase pathway. Cardiovasc Res 2011;89:614-22
   PubMed Web of Science ®Google Scholar
• Takemoto M, Sun J, Hiroki J, Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002;106:57-62
   PubMed Web of Science ®Google Scholar
• Schwenke DO, Pearson JT, Sonobe T, Role of Rho-kinase signaling and endothelial dysfunction in modulating blood flow distribution in pulmonary hypertension. J Appl Physiol 2011;110:901-8
   PubMedGoogle Scholar
• Xu EZ, Kantores C, Ivanovska J, Rescue treatment with a rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension. Am J Physiol Heart Circ Physiol 2010;299:H1854-64
   Google Scholar
• Chen XY, Dun JN, Miao QF, Zhang YJ. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway. Pharmacology 2009;83:67-79
   PubMedGoogle Scholar
• Fagan KA, Oka M, Bauer NR, Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 2004;287:L656-64
   PubMed Web of Science ®Google Scholar
• Yasuda T, Tada Y, Tanabe N, Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type 2 bone morphogenetic protein receptor gene. Am J Physiol Lung Cell Mol Physiol 2011;301:L667-74
   PubMedGoogle Scholar
• Abe K, Shimokawa H, Morikawa K, Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004;94:385-93
   PubMed Web of Science ®Google Scholar
• Abe K, Tawara S, Oi K, Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Pharmacol 2006;48:280-5
   PubMedGoogle Scholar
• Weigand L, Sylvester JT, Shimoda LA. Mechanisms of endothelin-1-induced contraction in pulmonary arteries from chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 2006;290:L284-90
   Google Scholar
• Guilluy C, Sauzeau V, Rolli-Derkinderen M, Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 2005;146:1010-18
   PubMed Web of Science ®Google Scholar
• Li F, Xia W, Li A, Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats. Pharmacol Res 2007;55:64-71
   PubMed Web of Science ®Google Scholar
• Nagaoka T, Fagan KA, Gebb SA, Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005;171:494-9
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Matoba T, Ito A, Acute vasodilator effects of a rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005;91:391-2
   PubMed Web of Science ®Google Scholar
• Fujita H, Fukumoto Y, Saji K, Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 2010;25:144-9
   PubMed Web of Science ®Google Scholar
• Doe C, Bentley R, Behm DJ, Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther 2007;320:89-98
   PubMed Web of Science ®Google Scholar
• Dhaliwal JS, Badejo AM Jr, Casey DB, Analysis of pulmonary vasodilator responses to sb-772077-B [4-(7-((3-amino-1-pyrrolidinyl)carbonyl)-1-ethyl-1H-imidazo(4,5-c)pyridin- 2-yl)-1,2,5-oxadiazol-3-amine], a novel aminofurazan-based Rho kinase inhibitor. J Pharmacol Exp Ther 2009;330:334-41
   PubMedGoogle Scholar
• Failli P, Alfarano C, Franchi-Micheli S, Losartan counteracts the hyper-reactivity to angiotensin II and ROCK1 over-activation in aortas isolated from streptozotocin-injected diabetic rats. Cardiovasc Diabetol 2009;8:32
   PubMedGoogle Scholar
• Shatanawi A, Romero MJ, Iddings JA, Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am J Physiol Cell Physiol 2011;300:C1181-92
   PubMed Web of Science ®Google Scholar
• Chassagne C, Eddahibi S, Adamy C, Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension. Am J Respir Cell Mol Biol 2000;22:323-32
   PubMedGoogle Scholar
• Bradford CN, Ely DR, Raizada MK. Targeting the vasoprotective axis of the renin-angiotensin system: a novel strategic approach to pulmonary hypertensive therapy. Curr Hypertens Rep 2010;12:212-19
   PubMed Web of Science ®Google Scholar
• Ferreira AJ, Shenoy V, Yamazato Y, Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009;179:1048-54
   PubMed Web of Science ®Google Scholar
• Xing XQ, Gan Y, Wu SJ, Statins may ameliorate pulmonary hypertension via RhoA/Rho-kinase signaling pathway. Med Hypotheses 2007;68:1108-13
   PubMed Web of Science ®Google Scholar
• Li M, Li Z, Sun X. Statins suppress MMP2 secretion via inactivation of RhoA/ROCK pathway in pulmonary vascular smooth muscles cells. Eur J Pharmacol 2008;591:219-23
   PubMed Web of Science ®Google Scholar
• Ikeda T, Nakamura K, Akagi S, Inhibitory effects of simvastatin on platelet-derived growth factor signaling in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol 2010;55:39-48
   PubMedGoogle Scholar
• Laudi S, Trump S, Schmitz V, Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol 2007;293:L630-8
   PubMed Web of Science ®Google Scholar
• Nishimura T, Vaszar LT, Faul JL, Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003;108:1640-5
   PubMed Web of Science ®Google Scholar
• Wilkins MR, Ali O, Bradlow W, Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med 2010;181:1106-13
   PubMed Web of Science ®Google Scholar
• Wu X, Somlyo AV, Somlyo AP. Cyclic GMP-dependent stimulation reverses G-protein-coupled inhibition of smooth muscle myosin light chain phosphatase. Biochem Biophys Res Commun 1996;220:658-63
   PubMedGoogle Scholar
• Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 2000;275:21722-9
   PubMed Web of Science ®Google Scholar
• Begum N, Sandu OA, Duddy N. Negative regulation of Rho signaling by insulin and its impact on actin cytoskeleton organization in vascular smooth muscle cells. Diabetes 2002;51:2256-63
   PubMedGoogle Scholar
• Morelli A, Filippi S, Sandner P, Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. J Sex Med 2009;6:1594-608
   PubMed Web of Science ®Google Scholar
• Li M, Sun X, Li Z, Liu Y. Inhibition of cGMP phosphodiesterase 5 suppresses serotonin signalling in pulmonary artery smooth muscles cells. Pharmacol Res 2009;59:312-18
   PubMed Web of Science ®Google Scholar